Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CSPC Pharmaceutical Group Limited (CSPCY)
Shijiazhuang, SP, CN
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 22 Rev. Ana. |
Dec 2027 20 Rev. Ana. |
|---|---|---|---|---|
| Revenue |
28.99B
est: 245.73B (-88.2%)
|
25.29B
est: 241.95B (-89.5%)
|
278.46B
246.38B – 333.66B
+15.1% YoY
|
275.36B
209.93B – 361.37B
-1.1% YoY
|
| EBITDA |
6.45B
est: 59.33B (-89.1%)
|
5.23B
est: 58.41B (-91.0%)
|
67.23B
59.49B – 80.56B
+15.1% YoY
|
66.48B
50.69B – 87.25B
-1.1% YoY
|
| EBIT |
5.43B
est: 50.08B (-89.2%)
|
3.86B
est: 49.31B (-92.2%)
|
56.75B
50.21B – 68.00B
+15.1% YoY
|
56.12B
42.78B – 73.64B
-1.1% YoY
|
| Net Income |
4.33B
|
3.78B
|
—
— – —
|
—
— – —
|
| SGA |
9.74B
est: 87.71B (-88.9%)
|
7.29B
est: 86.35B (-91.6%)
|
99.39B
87.94B – 119.09B
+15.1% YoY
|
98.28B
74.93B – 128.98B
-1.1% YoY
|
| EPS |
1.48
|
1.32
|
—
— – —
|
—
— – —
|
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CSPCY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
